Danish Biotech Weekly with insights to listed Danish biotech companies. We keep you updated on their news flow including updates on clinical trials, acquisitions, insider trading, price targets, right issues, etc.
In the past week, Genmab reported a positive phase 3 study with overall improved survival, Ascendis Pharma entered into an agreement worth 150 MUSD upfront, and SynAct Pharma got chrushed after a failed phase 2 study with their lead-candidate.
The past week was full of exciting news with 8 of the 20 listed Danish biotech companies publishing news. 10 of the 20 companies had a positive share price development the past week and 8 companies have a positive share price performance year to date. Fluoguide is back as the best performing stock year-to-date, while the SynAct Pharma stock price crashed.
Company news the past week
Ascendis Pharma
Ascendis Pharma Reports Second Quarter 2023 Financial Results (Link)
Ascendis Pharma and Royalty Pharma Enter into $150 Million Royalty Funding Agreement (Link)
New Post Hoc Analysis Showed Substantial Improvement in Observed Estimated Glomerular Filtration Rate (eGFR), in TransCon PTH-Treated Adults with Hypoparathyroidism (Link)
No news the past week
Cessatech
No news the past week
CS MEDICA’s Joint Venture with RongShi Successfully Represented at CPHI & PMEC China 2023 (Link)
No news the past week
Evaxion Biotech
No news the past week
Expres2ion
ExpreS2ion announces TO 8 warrant exercise price and start of exercise period (Link)
Fluoguide
FluoGuide receives Danish award for the best share price performance since IPO (Link)
Genmab
Genmab and Seagen Announce That TIVDAK® (tisotumab vedotin-tftv) Met its Primary Endpoint of Improved Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared to Chemotherapy (Link)
Gubra
Gubra submits clinical trial application (CTA) for first-in-human amylin trial (Link)
Initiator Pharma
No news the past week
IO Biotech
IO Biotech Announces Participation in Upcoming Investor Conferences (Link)
Pila Pharma
No news the past week
Saniona
No news the past week
Scandion Oncology
No news the past week
SynAct Pharma
Synact Pharma announces top line data from the 12-week EXPAND P2b clinical trial in severely active newly diagnosed rheumatoid arthritis patients (Link)
ViroGates
No news the past week
Zealand Pharma
Zealand Pharma to participate in upcoming healthcare conferences in September 2023 (Link)
Y-mAbs Therapeutics
Y-mAbs to Participate at Upcoming Investor Conferences in September (Link)
2cureX
No news the past week
SELECTED CASES
SHARE PRICE DEVELOPMENTS
On average, the Danish biotech stocks delivered a negative share price performance last week of -3.7%. Cessatech A/S rose more 60% without publishing any news. Ascendis Pharma ended up falling 1% after a deal with Royalty Pharma regarding SKYTROFA. Ascendis Pharma recieves $150 million in exchange for a 9.15% royalty on U.S. net SKYTROFA revenue. Furthermore, SynAct Pharma got chrushed with a 85% fall after their failed study, where Resomelagon did not meet the primary endpoint. The company still have preclinical studies with other compounds as well as Resomelagon in other indications but the failed study will have a significant impact on the company going forward. The best stocks year-to-date include Curasight, Cessatech Fluoguide, and Saniona after soaring 98-145%. Overall, the Danish biotech stocks are in positive terrotory this year with a year-to-date return of 0.3%. However, it is driven by the few companies delivering very positive returns.
Read more about Curasight (in Danish): Et succesfuldt kvartal for Curasight med mere i vente
Overview of share price developments the past week, year-to-date and last twelve months
